KRAS and cancer: Furthermore, treatment with 100 μM DMF for 24 h decreased HO-1, total NRF2 and total DJ-1 levels in the KRAS mutated P4; but not in the KRAS wild type P1 primary cancer cell lines (Figure 3C).